Lexaria Bioscience raises $4 million in registered direct offering

Lexaria Bioscience Corp. (NASDAQ: LEXX) announced it has entered into an agreement to sell 2,666,667 shares of common stock at $1.50 per share in a registered direct offering. The transaction is expected to generate approximately $4 million in gross proceeds before fees and expenses.

The offering includes warrants to purchase up to 2,666,667 additional shares at an exercise price of $1.37 per share. The warrants will be immediately exercisable and expire five years from the effectiveness of the resale registration statement. The closing is expected to occur on or about September 29, 2025, subject to customary closing conditions.

H.C. Wainwright & Co. is serving as the exclusive placement agent for the offering. The company stated it intends to use net proceeds for working capital and general corporate purposes.

The shares are being offered under a shelf registration statement on Form S-3 that was declared effective by the Securities and Exchange Commission on January 30, 2025. The warrants are being issued in a concurrent private placement and have not been registered under the Securities Act of 1933.

Lexaria develops DehydraTECH, a drug delivery platform technology designed to improve oral drug absorption. The company operates a research laboratory and holds 50 granted patents with additional patents pending worldwide.

You May Also Be Interested In

• Air T reports revenue jump but widens operating loss in Q1 fiscal 2027
• KKR to sell 5 million BridgeBio shares in secondary offering
• AI/ML Innovations plans $2M private placement on the CSE